Jia Liu

ORCID: 0000-0003-0490-5109
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Medical Imaging and Pathology Studies
  • Occupational and environmental lung diseases
  • Ferroptosis and cancer prognosis
  • Lung Cancer Research Studies
  • RNA modifications and cancer
  • Cancer therapeutics and mechanisms
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Cancer, Lipids, and Metabolism
  • Brain Metastases and Treatment
  • HER2/EGFR in Cancer Research
  • Lung Cancer Diagnosis and Treatment
  • Sarcoma Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Cystic Fibrosis Research Advances
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Neonatal Respiratory Health Research
  • Hematopoietic Stem Cell Transplantation
  • Gastric Cancer Management and Outcomes
  • Cancer, Hypoxia, and Metabolism
  • Immune Cell Function and Interaction
  • Radiopharmaceutical Chemistry and Applications
  • Acute Myeloid Leukemia Research
  • Nail Diseases and Treatments

Henan Cancer Hospital
2021-2025

Zhengzhou University
2021-2025

Shanghai Jiao Tong University
2025

Chongqing Cancer Hospital
2025

Chongqing University
2025

Chinese Academy of Medical Sciences & Peking Union Medical College
2013-2024

Peking Union Medical College Hospital
2012-2024

Xiamen University
2022-2024

Union Hospital
2023-2024

Huazhong University of Science and Technology
2023-2024

W. Marston Linehan Paul T. Spellman Christopher J. Ricketts Chad J. Creighton Suzanne S. Fei and 95 more Caleb Davis David A. Wheeler Bradley A. Murray Laura S. Schmidt Cathy D. Vocke Myron Peto Abu Amar M. Al Mamun Eve Shinbrot Anurag Sethi Samira A. Brooks W. Kimryn Rathmell Angela N. Brooks Katherine A. Hoadley A. Gordon Robertson Denise Brooks Reanne Bowlby Sara Sadeghi Hui Shen Daniel J. Weisenberger Arnoud Boot Stephen B. Baylin Peter W. Laird Andrew D. Cherniack Gordon Saksena Scott M. Haake Jun Li Liang Han Yiling Lu Gordon B. Mills Rehan Akbani Mark D.M. Leiserson Benjamin J. Raphael Pavana Anur Donald P. Bottaro Laurence Albigès Nandita Barnabas Toni K. Choueiri Bogdan Czerniak Andrew K. Godwin A. Ari Hakimi Thai H. Ho James J. Hsieh Michael Ittmann William Y. Kim Bhavani Krishnan Maria J. Merino Kenna Shaw Victor E. Reuter Ed Reznik Carl Simon Shelley Hai Hu Sabina Signoretti Ramaprasad Srinivasan Pheroze Tamboli George Thomas Satish K. Tickoo Kenneth Burnett Daniel Crain Johanna Gardner Kevin Lau David Mallery Scott Morris Joseph Paulauskis Robert Penny Candace Shelton W. Troy Shelton Mark E. Sherman Eric Thompson Peggy Yena Melissa Avedon Jay Bowen Julie M. Gastier-Foster Mark Gerken Kristen M. Leraas Tara M. Lichtenberg Nilsa C. Ramirez Tracie Santos Lisa Wise Erik Zmuda John A. Demchok Ina Felau Carolyn M. Hutter Margi Sheth Heidi J. Sofia Roy Tarnuzzer Zhining Wang Liming Yang Jean C. Zenklusen Jiashan Zhang Brenda Ayala Julien Baboud Sudha Chudamani Jia Liu Laxmi Lolla Rashi Naresh

Papillary renal-cell carcinoma, which accounts for 15 to 20% of carcinomas, is a heterogeneous disease that consists various types renal cancer, including tumors with indolent, multifocal presentation and solitary an aggressive, highly lethal phenotype. Little known about the genetic basis sporadic papillary no effective forms therapy advanced exist.We performed comprehensive molecular characterization 161 primary using whole-exome sequencing, copy-number analysis, messenger RNA microRNA...

10.1056/nejmoa1505917 article EN New England Journal of Medicine 2015-11-04

Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, including 488 clear RCC, 274 papillary 81 chromophobe RCC. Comprehensive genomic phenotypic analysis of subtypes reveals distinctive features each subtype that provide foundation for development subtype-specific management strategies patients...

10.1016/j.celrep.2018.03.075 article EN cc-by Cell Reports 2018-04-01

10.1016/j.ccell.2017.02.010 article EN Cancer Cell 2017-03-01

Abstract Atrial fibrillation (AF) is the most common clinical tachyarrhythmia with a strong tendency to progress in time. AF progression driven by derailment of protein homeostasis, which ultimately causes contractile dysfunction atria. Here we report that tachypacing-induced functional loss atrial cardiomyocytes precipitated excessive poly(ADP)-ribose polymerase 1 (PARP1) activation response oxidative DNA damage. PARP1-mediated synthesis ADP-ribose chains turn depletes nicotinamide adenine...

10.1038/s41467-019-09014-2 article EN cc-by Nature Communications 2019-03-21

10.1016/j.celrep.2018.06.032 article EN cc-by Cell Reports 2018-06-01

Immune checkpoint blockade (ICB) is a powerful oncologic treatment modality for wide variety of human malignancies, but the patient response rate to this remains low, especially in patients with cutaneous squamous cell carcinoma (cSCC). 5-Aminoleuvulinic acid-photodynamic therapy (ALA-PDT) widely used treat cancerous and precancerous skin diseases, value ALA-PDT invasive cSCC debatable. Our previous studies have shown that can induce antitumor immune responses by promoting immunogenic death...

10.1080/2162402x.2022.2061396 article EN cc-by-nc OncoImmunology 2022-04-03

Sarcoidosis is a systemic granulomatous disease, which thought to result from an aberrant immune response. CD4+ T lymphocytes play important role in the development of granulomas. Previously, immunopathogenesis sarcoidosis was focused on Th1/Th2 disturbances. The aim this study evaluate balance between newer lymphocytes, i.e., Treg and Th17 cells. In our studies, decrease cells increase were observed peripheral blood BALF patients. A significant Th17/Treg cell ratio After treatment with...

10.3390/ijms141121463 article EN International Journal of Molecular Sciences 2013-10-30

Abstract Luminescent metallo‐intercalators are potent biosensors of nucleic acid structure and anticancer agents targeting DNAs. There few examples luminescent which can simultaneously act as emission probes display promising activities. Herein, we describe a platinum(II) complex, [Pt(C^N^N)(C≡N t Bu)]ClO 4 ( 1 , HC^N^N= 6‐phenyl‐2,2′‐bipyridyl), that intercalates between the nucleobases acids, accompanied by an increase in intensity and/or significant change maximum wavelength. The changes...

10.1002/anie.201405384 article EN Angewandte Chemie International Edition 2014-07-15

AC0010 is a pyrrolopyrimidine-based irreversible EGFR inhibitor, structurally distinct from previously reported pyrimidine-based inhibitors, such as osimertinib and rociletinib. selectively inhibits EGFR-active T790M mutations with up to 298-fold increase in potency compared wild-type EGFR. In xenograft model, oral administration of at daily dose 500 mg/kg resulted complete remission tumors for over 143 days no weight loss. Three major metabolites were tested showed inhibition or off-target...

10.1158/1535-7163.mct-16-0281 article EN Molecular Cancer Therapeutics 2016-08-30

Purpose: No validated biomarkers that could identify the subset of patients with lung adenocarcinoma who might benefit from chemotherapy have yet been well established. This study aimed to explore potential biomarker model predictive efficacy and survival outcomes after first-line pemetrexed plus platinum doublet based on metabolomics profiling.Experimental Design: In total, 354 consecutive eligible were assigned receive in combination either cisplatin or carboplatin. Prospectively collected...

10.1158/1078-0432.ccr-17-2855 article EN Clinical Cancer Research 2018-02-06

Background Early-onset scoliosis (EOS), defined by an onset age of less than 10 years, conveys significant health risk to affected children. Identification the molecular aetiology underlying patients with EOS could provide valuable information for both clinical management and prenatal screening. Methods In this study, we consecutively recruited a cohort 447 Chinese operative EOS. We performed exome sequencing (ES) screening on these individuals their available family members (totaling 670...

10.1136/jmedgenet-2019-106823 article EN Journal of Medical Genetics 2020-05-07

Idiopathic pulmonary fibrosis is a progressive and lethal form of interstitial lung disease that lacks effective therapies at present. Glycyrrhizic acid (GA), natural compound extracted from traditional Chinese herbal medicine Glycyrrhiza glabra, was recently reported to benefit injury liver in animal models, yet whether GA has therapeutic effect on unknown. In this study, we investigated the potential rat model with bleomycin (BLM)-induced fibrosis. The results indicated treatment...

10.3389/fphar.2015.00215 article EN cc-by Frontiers in Pharmacology 2015-10-01

Viral infection often causes severe damage to the lungs, leading appearance of ectopic basal cells (EBCs) and tuft in lung parenchyma. Thus far, roles these epithelial alveolar regeneration remain controversial. Here, we confirm that are originated from EBCs mouse models COVID-19 lungs. The differentiation is promoted by Wnt inhibition while suppressed Notch inhibition. Although progenitor functions have been suggested other organs, pulmonary don’t proliferate or give rise cell lineages....

10.7554/elife.78217 article EN cc-by eLife 2022-09-21

Crocus sativus, containing remarkably amounts of crocin, picrocrocin and safranal, is the source saffron with tremendous medicinal, economic cultural importance. Here, we present a high-quality full-length transcriptome sterile triploid C. using PacBio SMRT sequencing technology. This yields 31,755 high-confidence predictions protein-coding genes, 50.1% forming paralogous gene pairs. Analysis on distribution Ks values suggests that current genome sativus probably product resulting from at...

10.1016/j.csbj.2020.03.022 article EN cc-by Computational and Structural Biotechnology Journal 2020-01-01

Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly understood, especially in a real‐world setting. Methods A multicenter observational study was conducted. Medical records of cancer patients treated with ICIs at 26 hospitals from January 1, 2015, to February 28, 2021, were retrieved. Types included antiprogrammed cell death 1 or ligand (PD‐L1) monotherapy, anticytotoxic...

10.1111/1759-7714.14274 article EN Thoracic Cancer 2021-12-21
Coming Soon ...